Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF
Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF
Recruiting · NCT07776054 · Registry updated 2026-08-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder | Recruiting | Phase 4 | 2026-08-20 | NCT07776054 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Samsung Medical Center | 207 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Samsung Medical Center | Seoul | South Korea | 42 |